Hospitalization of Adolescents Aged 12-17 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1, 2020-April 24, 2021.
Journal
MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
entrez:
10
6
2021
pubmed:
11
6
2021
medline:
12
6
2021
Statut:
epublish
Résumé
Most COVID-19-associated hospitalizations occur in older adults, but severe disease that requires hospitalization occurs in all age groups, including adolescents aged 12-17 years (1). On May 10, 2021, the Food and Drug Administration expanded the Emergency Use Authorization for Pfizer-BioNTech COVID-19 vaccine to include persons aged 12-15 years, and CDC's Advisory Committee on Immunization Practices recommended it for this age group on May 12, 2021.* Before that time, COVID-19 vaccines had been available only to persons aged ≥16 years. Understanding and describing the epidemiology of COVID-19-associated hospitalizations in adolescents and comparing it with adolescent hospitalizations associated with other vaccine-preventable respiratory viruses, such as influenza, offers evidence of the benefits of expanding the recommended age range for vaccination and provides a baseline and context from which to assess vaccination impact. Using the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET), CDC examined COVID-19-associated hospitalizations among adolescents aged 12-17 years, including demographic and clinical characteristics of adolescents admitted during January 1-March 31, 2021, and hospitalization rates (hospitalizations per 100,000 persons) among adolescents during March 1, 2020-April 24, 2021. Among 204 adolescents who were likely hospitalized primarily for COVID-19 during January 1-March 31, 2021, 31.4% were admitted to an intensive care unit (ICU), and 4.9% required invasive mechanical ventilation; there were no associated deaths. During March 1, 2020-April 24, 2021, weekly adolescent hospitalization rates peaked at 2.1 per 100,000 in early January 2021, declined to 0.6 in mid-March, and then rose to 1.3 in April. Cumulative COVID-19-associated hospitalization rates during October 1, 2020-April 24, 2021, were 2.5-3.0 times higher than were influenza-associated hospitalization rates from three recent influenza seasons (2017-18, 2018-19, and 2019-20) obtained from the Influenza Hospitalization Surveillance Network (FluSurv-NET). Recent increased COVID-19-associated hospitalization rates in March and April 2021 and the potential for severe disease in adolescents reinforce the importance of continued COVID-19 prevention measures, including vaccination and correct and consistent wearing of masks by persons not yet fully vaccinated or when required by laws, rules, or regulations.
Identifiants
pubmed: 34111061
doi: 10.15585/mmwr.mm7023e1
pmc: PMC8191866
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
851-857Investigateurs
Gretchen Rothrock
(G)
Arthur Reingold
(A)
Millen Tsegaye
(M)
Sarah McLafferty
(S)
Amber Maslar
(A)
Paula Clogher
(P)
Adam Misiorski
(A)
Christina Parisi
(C)
Maria Correa
(M)
Tessa Carter
(T)
Carol Lyons
(C)
Daewi Kim
(D)
Gaggan Brar
(G)
Emily Fawcett
(E)
Allison Roebling
(A)
Katelyn Ward
(K)
Jana Manning
(J)
Asmith Joseph
(A)
Chandler Surell
(C)
Daniel Pizarro
(D)
Jeremiah Williams
(J)
Rayna Ceaser
(R)
Stephanie Lehman
(S)
Taylor Eisenstein
(T)
Gracie Chambers
(G)
Grayson Kallas
(G)
Lauren Russell
(L)
Suzanne Segler
(S)
David Blythe
(D)
Alicia Brooks
(A)
Erica Bye
(E)
Richard Danila
(R)
Cory Cline
(C)
Susan Ropp
(S)
Chad Smelser
(C)
Daniel Sosin
(D)
Salina Torres
(S)
Kathy Angeles
(K)
Melissa Christian
(M)
Nancy Eisenberg
(N)
Kristina Flores
(K)
Caroline Habrun
(C)
Emily Hancock
(E)
Sarah Khanlian
(S)
Meaghan Novi
(M)
Erin Phipps
(E)
Dominic Rudin
(D)
Yadira Salazar-Sanchez
(Y)
Judith Segall
(J)
Sarah Shrum Davis
(SS)
Grant Barney
(G)
Christina Felsen
(C)
Sophrena Bushey
(S)
Kevin Popham
(K)
Virginia Cafferky
(V)
Christine Long
(C)
RaeAnne Kurtz
(R)
Nicole West
(N)
Ama Owusu-Dommey
(A)
Breanna McArdle
(B)
Emily Youngers
(E)
Kylie Seeley
(K)
Tiffanie Markus
(T)
Amanda Carter
(A)
Andrea Price
(A)
Andrew Haraghey
(A)
Ashley Swain
(A)
Caitlin Shaw
(C)
Ian Buchta
(I)
Jake Ortega
(J)
Laine McCullough
(L)
Ryan Chatelain
(R)
Tyler Riedesel
(T)
Déclaration de conflit d'intérêts
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Andrea George, Laurie M. Billing, Libby Reeg, Alexander Kohrman, Andrew Weigel, Kenzie Teno, and Jess Shiltz report grant funding from the Council of State and Territorial Epidemiologists. William Schaffner reports personal fees from VBI Vaccines. Evan J. Anderson reports grants for clinical trials from Pfizer, Merck, PaxVax, Micron, Sanofi-Pasteur, Janssen, MedImmune and GSK, and personal fees for consulting from Sanofi-Pasteur, Pfizer, and Medscape, and for data safety monitoring board service from Kentucky Bioprocessing, Inc. and Sanofi-Pasteur; and funding from the National Institutes of Health to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. No other potential conflicts of interest were disclosed.
Références
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
JAMA Pediatr. 2020 Sep 1;174(9):868-873
pubmed: 32392288
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1081-1088
pubmed: 32790664
Emerg Infect Dis. 2015 Sep;21(9):1543-50
pubmed: 26291121
J Infect Dis. 2021 Feb 13;223(3):362-369
pubmed: 33119738
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):141-143
pubmed: 33507895
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):674-679
pubmed: 33956782
Ann Intern Med. 2021 Mar;174(3):362-373
pubmed: 33253040